30 closest matches · ranked by relevance
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz) — -0.1372; -0.0893; -0.2167; 0.3215 z-score — p=0.15
Breast Cancer
Primary: Maximum Change in LVEF at 3 Months — 1; -5 change in percent ejection fraction
Cardiotoxicity · Risk Factor, Cardiovascular · Toxicity Due to Chemotherapy
Primary: Left Ventricular Ejection Fraction (LVEF) — 61.1; 59.0; 61.9; 58.4 percent
Degradation of Top2b and Top2a in Human by Dexrazoxane · Time Course and Degradation of Top2b in Human by Dexrazoxane · Effects of Dexrazoxane on Healthy Human
Primary: Participants With 95% Reduction in Topoisomerase 2 b From Baseline — 0; 0; 0; 0 Participants
Breast Cancer
Primary: LVEF — 65.4; 64.7; 62.2 percentage of blood in left ventricle — p=<0.0005
Heart Failure
Primary: The Percentage of Individuals in Each Group With a Significant Decline in the LVEF. — 22; 9 Participants
Breast Cancer
Primary: Pre-operative Concentration of NT-proBNP — 38.9; 32.2 pg/ml — p=0.714
Breast Cancer
Primary: Global Longitudinal Strain — 19.2; -19.6; 21.4; -21.5 % deformation
Cardiomyopathy
Primary: Change in Left Ventricular Ejection Fraction — 10.6 percentage of LVEF
Cardiac Toxicity · Chemotherapeutic Agent Toxicity · Lymphoma
Primary: Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy — 5; 5 Participants
HER2 Positive Breast Cancer · Left Ventricular Function Systolic Dysfunction
Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants
Breast Cancer · Lymphoma
Primary: Left Ventricular Ejection Fraction (LVEF) — 58.1; 57.9 percent ejected from LV per heartbeat — p=0.84
Cardiac Toxicity · Malignant Neoplasm · Breast Cancer
Primary: Number of Participants Completing the Trial (Exercise Capacity Addendum) — 17; 8 Participants
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) of MTD/Phase II Patients — 4.0 months
Breast Cancer
Primary: Percentage of Participants Exhibiting a Pathological Complete Response (pCR) in Breast — 41.3; 54.0 percentage of participants — p=0.154
Breast Neoplasm
Primary: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to…
Cardiomyopathy Due to Anthracyclines
Primary: Proportion of Major Adverse Cardiac Events (MACE) — 3; 6 events
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8 · Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Primary: Proportion of Participants With a Cardiac Event at 12 Months — 0.6818 proportion of participants
Breast Cancer
Primary: Number of Patients With Doxorubicin Plasma Concentrations Demonstrating a Significant Increase or Decrease When Doxorubicin Was Given With Enalapril as Compared to When…
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Maximum Tolerated Dose and Optimal Tolerated Dose of Pegylated Liposomal Doxorubicin Hydrochloride (Doxil) When Given in Combination With Cyclophosphamide (Phase I) — 30…
Duchenne Muscular Dystrophy
Primary: 12-month Change in Myocardial Strain — 2.2; 1.0 percent change in heart dimension
Breast Cancer
Primary: LVEF Results — -8; -6 LVEF Percentage (%)
Breast Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 28; 31 percentage of patients
Hypertension · Dyslipidemias · Diabetes
Primary: Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c…
Node Positive Breast Cancer
Primary: Cardiac MRI Parameters — 0; 0; 0; 0 number of patients
Relapsed Pediatric ALL · Relapsed Pediatric AML · Refractory Acute Myeloid Leukemia
Primary: Incidence of Low Dose Daunorubicin Feasbility as Assessed by Absolute Blast Count — 0; 1 Participants
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Dilated Cardiomyopathy
Primary: Heart Failure Mortality — 8; 19 participants — p=0.01
Dilated Cardiomyopathy
Primary: Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs. — 1 Participants
Invasive Breast Cancer
Primary: Rate of Achievement of Pathological Complete Response (pCR) — 9 pathology specimens from participants